Maryland biotech subsidiary gets $50M in funding to further cell therapy manufacturing

The new subsidiary, Morgenesis, will be located at the Maryland Center for Cell Therapy Manufacturing, a collaboration between the company and Johns Hopkins Medicine. The company hopes make it more affordable for startups and universities to create cell therapies for clinical trials.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.